An interventional study of Triamcinolone Acetonide and Bupivacaine Hydrochloride in Chronic Knee Pain, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Triamcinolone Acetonide in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. Triamcinolone Acetonide · Pain.
Among the 17 studies testing Triamcinolone Acetonide in Pain, this one is the 10th largest by planned enrollment, is the only one that started in 2024, is one of 2 with no phase, and was the 14th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →4 of the 17 studies testing Triamcinolone Acetonide in Pain are open now, in 3 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Harrow Inc · Sites in United States
Ages 18+
Allama Iqbal Medical College · Sites in Pakistan
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 81 across the 17 interventional studies. Of the 13 that completed or were terminated, 12 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 17 have an industry lead sponsor. The 6 most frequent:
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
32 studies in Pain by Tanta University: 10 open now, 10 under way, 1 of them phase 3. Of 21 finished, 0 (0%) have results posted.
Among the 32 studies in Pain by Tanta University, this one is the 14th largest by planned enrollment, is one of 11 that started in 2024, is one of 30 with no phase, and was the 16th registered.
Tanta University’s Pain studies by the year they started, since 2020.
1 of the studies testing Triamcinolone Acetonide in Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07832552Phase 3Harrow IncA Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing Triamcinolone Acetonide in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Tanta University’s 32 in Pain:
This tab as a report to print or save as PDF → With an account.
Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A group of Patients from Tanta University suffering from Chronic painful knee osteoarthritis who didn't receive medical treatment and progressed to have chronic pain with decreased physical function and poorer quality of life.
Drug: Triamcinolone Acetonide · Drug: Bupivacaine Hydrochloride
A group of Patients from Tanta University suffering from Chronic painful knee osteoarthritis who didn't receive medical treatment and progressed to have chronic pain with decreased physical function and poorer quality of life.
Drug: Dexmedetomidine
1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-intra-articular Injection.
Value of intra-articular Injection in Pain Reduction of chronic knee pain manifested by recurrence of pain.
Time frame: 7 months
Started Sep 2024 (actual). Primary completion is estimated for Jan 2025, 4 months after the start.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 4 months is below that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Triamcinolone Acetonide · Bupivacaine · Dexmedetomidine